is metformin a glp-1 drug vs. Ozempic: Which for Weight Loss, Prediabetes, PCOS, and More Metformin-Enhanced Digital Therapeutics for the

The growing health awareness and presence of robust healthcare systems are increasing accessibility, where companies are collaborating to develop their new formulations

Initially, the NHS has made Mounjaro available to patients at greatest risk of ill health, or who are experiencing severe ill health due to living with obesity

130 , 833841.e3 (2017)

Participants taking tirzepatide lost an average of 15.3% of their body weight after a year, while those on semaglutide lost about 8.3%

We need safer alternatives

GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure